Aurinia Pharmaceuticals Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Kevin Tang (CEO) and Michael Hearne (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications on August 5, 2026 for the quarterly report ended June 30, 2026. They certify the report contains no material misstatements, financial statements fairly present the company's condition, and disclosure controls and internal controls over financial reporting are effective. No specific financial data, transactions, or control deficiencies are disclosed in these certification exhibits.
Why this rating
Routine SOX certification exhibits; no business events, transactions, or control issues disclosed. Standard periodic compliance filing.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.